Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Bargay

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Leukemia Research|August 13, 2005
Adverse prognostic impact of CD36 and CD2 expression in adult de novo acute myeloid leukemia patientsG Perea, A Domingo, N Villamor, et al.
Sangre|April 1, 1997
[Allogenic transplant of non-manipulated hematopoietic progenitor peripheral blood cells. Spanish experience of 79 cases. Allo-Peripheral Blood Transplantation Group]S Brunet, A Urbano-Ispizua, C Solano, et al.
Leukemia Research|June 15, 2010
Immunophenotype of acute myeloid leukemia with NPM mutations: prognostic impact of the leukemic compartment sizeJ Nomdedeu, E Bussaglia, N Villamor, et al.
Bone Marrow Transplantation|October 12, 1999
Administration of recombinant human granulocyte colony-stimulating factor to normal donors: results of the Spanish National Donor Registry. Spanish Group of Allo-PBTJ de la Rubia, C Martínez, C Solano, et al.
Leukemia|November 11, 2005
Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]G Perea, A Lasa, A Aventín, et al.
Blood Cancer Journal|October 3, 2015
The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemiaM Díaz-Beyá, S Brunet, J Nomdedéu, et al.
British Journal of Haematology|September 13, 2001
Favourable effect of the combination of acute and chronic graft-versus-host disease on the outcome of allogeneic peripheral blood stem cell transplantation for advanced haematological malignanciesS Brunet, A Urbano-Ispizua, E Ojeda, et al.
Bone Marrow Transplantation|September 26, 2001
Allogeneic transplantation of CD34+-selected cells from peripheral blood in patients with myeloid malignancies in early phase: a case control comparison with unmodified peripheral blood transplantationA Urbano-Ispizua, S Brunet, C Solano, et al.
British Journal of Haematology|June 10, 2000
Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish Registry for Transplantation in Multiple MyelomaJ J Lahuerta, J Martinez-Lopez, C Grande, et al.
Leukemia|February 18, 2017
Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myelomaJ Martinez-Lopez, B Sanchez-Vega, S Barrio, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Leukemia Research|August 13, 2005
Adverse prognostic impact of CD36 and CD2 expression in adult de novo acute myeloid leukemia patientsG Perea, A Domingo, N Villamor, et al.
Sangre|April 1, 1997
[Allogenic transplant of non-manipulated hematopoietic progenitor peripheral blood cells. Spanish experience of 79 cases. Allo-Peripheral Blood Transplantation Group]S Brunet, A Urbano-Ispizua, C Solano, et al.
Leukemia Research|June 15, 2010
Immunophenotype of acute myeloid leukemia with NPM mutations: prognostic impact of the leukemic compartment sizeJ Nomdedeu, E Bussaglia, N Villamor, et al.
Bone Marrow Transplantation|October 12, 1999
Administration of recombinant human granulocyte colony-stimulating factor to normal donors: results of the Spanish National Donor Registry. Spanish Group of Allo-PBTJ de la Rubia, C Martínez, C Solano, et al.
Leukemia|November 11, 2005
Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]G Perea, A Lasa, A Aventín, et al.
Blood Cancer Journal|October 3, 2015
The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemiaM Díaz-Beyá, S Brunet, J Nomdedéu, et al.
British Journal of Haematology|September 13, 2001
Favourable effect of the combination of acute and chronic graft-versus-host disease on the outcome of allogeneic peripheral blood stem cell transplantation for advanced haematological malignanciesS Brunet, A Urbano-Ispizua, E Ojeda, et al.
Bone Marrow Transplantation|September 26, 2001
Allogeneic transplantation of CD34+-selected cells from peripheral blood in patients with myeloid malignancies in early phase: a case control comparison with unmodified peripheral blood transplantationA Urbano-Ispizua, S Brunet, C Solano, et al.
British Journal of Haematology|June 10, 2000
Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish Registry for Transplantation in Multiple MyelomaJ J Lahuerta, J Martinez-Lopez, C Grande, et al.
Leukemia|February 18, 2017
Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myelomaJ Martinez-Lopez, B Sanchez-Vega, S Barrio, et al.
Pageof 4